BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/2/2015 11:56:00 AM | Browse: 488 | Download: 653
Publication Name World Journal of Pharmacology
Manuscript ID 15659
Country/Territory United Kingdom
Received
2014-12-02 08:41
Peer-Review Started
2014-12-02 10:32
To Make the First Decision
2015-02-07 14:52
Return for Revision
2015-02-10 13:48
Revised
2015-02-22 03:23
Second Decision
2015-04-01 15:24
Accepted by Journal Editor-in-Chief
2015-04-01 18:12
Accepted by Company Editor-in-Chief
2015-04-14 16:05
Articles in Press
2015-04-14 16:06
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2015-06-01 16:00
Publish the Manuscript Online
2015-06-19 15:32
ISSN 2220-3192 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Review
Article Title Progress in pancreatic cancer therapeutics: The potential to exploit molecular targets
Manuscript Source Invited Manuscript
All Author List Kiruthikah Thillai, Debashis Sarker and Paul Ross
Funding Agency and Grant Number
Corresponding author Dr. Paul Ross, Department of Medical Oncology, Guy’s and St Thomas NHS Trust, Great Maze Pond, SE19RT London, United Kingdom. paul.ross@gstt.nhs.uk
Key Words Pancreatic cancer; Adenocarcinoma; Targ­eted therapy; Genomics; Stroma; KRAS; Chemo­therapy
Core Tip Pancreatic ductal adenocarcinoma is a cancer with several significant genetic aberrations that have recently been identified by international research efforts. Despite these findings, standard therapy for advanced disease consists primarily of chemotherapy. In the last few years two new chemotherapy regimens, FOLFIRINOX and Gemcitabine/Nab-paclitaxel, have demonstrated survival benefits in large phase III trials resulting in a change to current practise. However, the advent of targeted treatments has not yet had a significant impact in this disease compared with other malignancies. Current research strategies include developing therapies directed towards the RAS-RAK-MEK pathway, PI3K-AKT-mTOR pathway, notch pathway and immunotherapies to name but a few, with several clinical trials underway. It is likely that the hetero-geneous nature of pancreatic cancer necessitates a more persona-lised approach to management with targeted treatment guided by predictive biomarkers.
Publish Date 2015-06-19 15:32
Citation Thillai K, Sarker D, Ross P. Progress in pancreatic cancer therapeutics: The potential to exploit molecular targets. World J Pharmacol 2015; 4(2): 180-192
Url http://www.wjgnet.com/2220-3192/full/v4/i2/180.htm
DOI http://dx.doi.org/10.5497/wjp.v4.i2.180
Full Article (PDF) WJP-4-180.pdf
Full Article (Word) WJP-4-180.doc
Manuscript File 15659-Review.doc
Answering Reviewers 15659-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form 15659-Conflict-of-interest statement.pdf
Copyright License Agreement 15659-Copyright assignment.pdf
Peer-review Report 15659-Peer-review(s).pdf
Journal Editor-in-Chief Review Report 15659-Journal editor-in-chief review report.pdf
Scientific Misconduct Check 15659-Scientific misconduct check.pdf
Scientific Editor Work List 15659-Scientific editor work list.pdf